Business Context and Reporting Period
Apimeds Pharmaceuticals US, Inc. (APUS) filed a Form 8-K on May 16, 2025, reporting the entry into a material definitive agreement. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Hopewell, New Jersey.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, or operating margins. The document focuses exclusively on debt restructuring.
- Total Debt Affected: $500,000 in principal amount across three promissory notes.
- Interest Rate: 5% per annum on all notes.
- Lenders: Inscobee Inc. ($250,000 total) and Apimeds Inc. ("Apimeds Korea") ($250,000).
Material Changes Versus Prior Period
The Company amended the terms of three outstanding promissory notes originally issued between May 2024 and March 2025.
- May 2024 Note: $100,000 principal. Original maturity was the earlier of an equity financing of $3,000,000 or May 19, 2025.
- August 2024 Note: $150,000 principal. Original maturity was the earlier of an equity financing of $3,000,000 or May 19, 2025.
- March 2025 Note: $250,000 principal. Original maturity was the earlier of December 31, 2026, or the listing of Common Stock on a national securities exchange.
- Change: All three notes were amended to extend the maturity date to May 19, 2026.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operations, or specific risk factors beyond the terms of the debt amendments. The extension of the debt maturity dates suggests the Company has not yet met the original equity financing or listing triggers that would have accelerated repayment.
Investor Verification Checklist
- Verify the current status of the Company's equity financing efforts to determine if the $3,000,000 threshold has been met.
- Confirm whether the Common Stock is currently listed on the NYSE American or another national exchange, as this impacts the original maturity terms of the March 2025 Note.
- Review the full text of the Amendment (Exhibit 10.1) for any additional covenants or conditions not summarized in the 8-K.
- Check subsequent filings for any further amendments or defaults on the extended notes.